StreetInsider.com News Articles

Form 4 ANI PHARMACEUTICALS INC For: Oct 15 Filed by: Lalwani Nikhil

Fri, 16 Oct 2026 18:50:00 -0400

si-local-file:///var/storage/secattach/20261016/27198933.html

Form 144 ANI PHARMACEUTICALS INC Filed by: Lalwani Nikhil

Thu, 15 Oct 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20261015/27193720.html

Form 4 ANI PHARMACEUTICALS INC For: Oct 13 Filed by: Cook Meredith

Tue, 13 Oct 2026 20:48:00 -0400

si-local-file:///var/storage/secattach/20261013/27182330.html

ANI Pharmaceuticals reports positive phase 4 uveitis trial data

Mon, 12 Oct 2026 06:55:17 -0400

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced results from its SYNCHRONICITY Phase 4 clinical trial evaluating a fluocinolone acetonide intravitreal implant (0.18 mg) in patients with chronic non-infectious uveitis affecting the posterior segment of the eye (chronic NIU-PS), presented at the American Academy of Ophthalmology 2026 Annual Meeting in New Orleans.

The trial met both co-primary endpoints with statistical significance in the intent-to-treat population of 108 patients at six months. Patients gained a mean of 3.6 letters in best corrected visual acuity (p=0.0077), while mean central subfield thickness decreased by 157.5 microns (p<0.0001).

At 24 months, mean BCVA improvement reached +5.5 letters and

ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 An

Mon, 12 Oct 2026 06:55:00 -0400

Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline in CST with statistical significance¹ at 6 months, and these changes were maintained at 24 months (a key secondary endpoint)
The most common adverse events reported were consistent with prior trials of fluocinolone acetonide intravitreal implant 0.18 mg
Study evaluated patients with chronic NIU-PS in the U.S.; most patients in the study were treated by retina specialists

PRINCETON, N.J., Oct. 12, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals,

ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 An

Mon, 12 Oct 2026 06:55:00 -0400

Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline in CST with statistical significance¹ at 6 months, and these changes were maintained at 24 months (a key secondary endpoint)
The most common adverse events reported were consistent with prior trials of fluocinolone acetonide intravitreal implant 0.18 mg
Study evaluated patients with chronic NIU-PS in the U.S.; most patients in the study were treated by retina specialists

PRINCETON, N.J., Oct. 12, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals,

Form 4 ANI PHARMACEUTICALS INC For: Sep 29 Filed by: CAREY STEPHEN P.

Wed, 30 Sep 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260930/27129249.html

ANI Pharmaceuticals to present eye implant data at AAO 2026 meeting

Wed, 30 Sep 2026 06:55:40 -0400

ANI Pharmaceuticals (Nasdaq: ANIP) announced it will present clinical trial data on its Fluocinolone Acetonide Intravitreal Implant at the American Academy of Ophthalmology 2026 Annual Meeting in New Orleans.

Data from the Phase 4 SYNCHRONICITY trial, which studied the implant in patients with chronic non-infectious uveitis affecting the posterior segment of the eye, will be delivered in a late-breaking oral presentation during Uveitis Subspecialty Day on October 9, 2026. David Almeida, MD, PhD, MBA, President and CEO of Erie Retina Research and principal investigator in SYNCHRONICITY, will present the findings.

The SYNCHRONICITY results follow six-month topline data the company announced in July

ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting

Wed, 30 Sep 2026 06:55:00 -0400

Data from Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day 2026

Post-hoc analyses of baseline characteristics and efficacy outcomes in rescued and non-rescued patients from the Phase 4 NEW DAY trial will be presented in an on-demand ePoster

PRINCETON, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that data from SYNCHRONICITY, its Phase 4, open-label, single-arm clinical trial of Fluocinolone Acetonide Intravitreal Implant in patients with chronic non-infectious uveitis affecting the posterior segment

ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting

Wed, 30 Sep 2026 06:55:00 -0400

Data from Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day 2026

Post-hoc analyses of baseline characteristics and efficacy outcomes in rescued and non-rescued patients from the Phase 4 NEW DAY trial will be presented in an on-demand ePoster

ANI Pharmaceuticals gets FDA approval for generic everolimus suspension

Wed, 23 Sep 2026 06:55:14 -0400

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced it received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Everolimus Tablets for Oral Suspension in 2mg, 3mg, and 5mg doses.

The approved product is a generic version of Afinitor Disperz, a branded drug. U.S. annual sales for Everolimus Tablets for Oral Suspension totaled approximately $123 million, based on July 2026 moving annual total data from IQVIA.

"The FDA approval of Everolimus Tablets for Suspension is another example of our R&D team's continued execution on technically demanding formulations, and the launch adds further momentum to our commercial portfolio,"

ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension

Wed, 23 Sep 2026 06:55:00 -0400

PRINCETON, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), for Everolimus Tablets for Oral Suspension 2mg, 3mg and 5mg. ANI’s Everolimus Tablets for Oral Suspension are the generic version of the reference listed drug (RLD) Afinitor Disperz^®.

"The FDA approval of Everolimus Tablets for Suspension is another example of our R&D team's continued execution on technically demanding formulations, and the launch adds further momentum to

ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension

Wed, 23 Sep 2026 06:55:00 -0400

"The FDA approval of Everolimus Tablets for Suspension is another example of our R&D team's continued execution on technically demanding formulations, and the launch adds further momentum to

Oppenheimer Starts ANI Pharmaceuticals (ANIP) at Perform

Wed, 23 Sep 2026 06:10:51 -0400

(Updated - September 23, 2026 6:10 AM EDT)

Oppenheimer initiates coverage on ANI Pharmaceuticals (NASDAQ: ANIP) with a Perform rating and a price target of $85.00.

The analyst comments "We initiate coverage of ANI Pharmaceuticals with a Perform rating and $85 PT. Cortrophin Gel remains an attractive, durable rare disease asset, but the valuation increasingly reflects sustained elevated growth despite management’s recent 5% reduction to 2026 midpoint guidance. The acute gout expansion broadens the opportunity but requires significant commercial investment, carries lower utilization per patient and faces meaningful access friction. Iluvien provides diversification but has yet to establish a sustained growth trajectory

Oppenheimer Starts ANI Pharmaceuticals (ANIP) at Perform

Wed, 23 Sep 2026 06:10:51 -0400

(Updated - September 23, 2026 6:10 AM EDT)

Oppenheimer initiates coverage on ANI Pharmaceuticals (NASDAQ: ANIP) with a Perform rating and a price target of $85.00.

Form 4 ANI PHARMACEUTICALS INC For: Aug 25 Filed by: Lalwani Nikhil

Fri, 18 Sep 2026 12:39:00 -0400

si-local-file:///var/storage/secattach/20260918/27079734.html

Form 4 ANI PHARMACEUTICALS INC For: Sep 15 Filed by: Lalwani Nikhil

Wed, 16 Sep 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260916/27070535.html

Form 144 ANI PHARMACEUTICALS INC Filed by: Lalwani Nikhil

Tue, 15 Sep 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260915/27065174.html

Form 4 ANI PHARMACEUTICALS INC For: Sep 14 Filed by: Cook Meredith

Mon, 14 Sep 2026 20:57:00 -0400

si-local-file:///var/storage/secattach/20260914/27059786.html

Form 4 ANI PHARMACEUTICALS INC For: Sep 11 Filed by: Thoma Jeanne

Mon, 14 Sep 2026 20:57:00 -0400

si-local-file:///var/storage/secattach/20260914/27059787.html

Form 144 ANI PHARMACEUTICALS INC Filed by: Thoma Jeanne

Fri, 11 Sep 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260911/27053268.html

Leerink Starts ANI Pharmaceuticals (ANIP) at Outperform

Wed, 09 Sep 2026 06:49:09 -0400

Leerink analyst Daniel Clark initiates coverage on ANI Pharmaceuticals (NASDAQ: ANIP) with a Outperform rating and a price target of $104.00.

For an analyst ratings summary and ratings history on ANI Pharmaceuticals click here. For more ratings news on ANI Pharmaceuticals click here.

Shares of ANI Pharmaceuticals closed at $70.23 yesterday.

ANI Pharmaceuticals to Present at September Investor Conferences

Thu, 03 Sep 2026 06:55:00 -0400

PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company’s executive leadership team, will participate in fireside chats at the following upcoming investor conferences:

ANI Pharmaceuticals to Present at September Investor Conferences

Thu, 03 Sep 2026 06:55:00 -0400








	Form 4 ANI PHARMACEUTICALS INC For: Aug 19 Filed by: Gosebruch Henry O Thu, 27 Aug 2026 16:22:00 -0400 si-local-file:///var/storage/secattach/20260827/26990337.html

StreetInsider.com News Articles

Form 4 ANI PHARMACEUTICALS INC For: Oct 15 Filed by: Lalwani Nikhil

Form 144 ANI PHARMACEUTICALS INC Filed by: Lalwani Nikhil

Form 4 ANI PHARMACEUTICALS INC For: Oct 13 Filed by: Cook Meredith

ANI Pharmaceuticals reports positive phase 4 uveitis trial data

ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 An

ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 An

Form 4 ANI PHARMACEUTICALS INC For: Sep 29 Filed by: CAREY STEPHEN P.

ANI Pharmaceuticals to present eye implant data at AAO 2026 meeting

ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting

ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting

ANI Pharmaceuticals gets FDA approval for generic everolimus suspension

ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension

ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension

Oppenheimer Starts ANI Pharmaceuticals (ANIP) at Perform

Oppenheimer Starts ANI Pharmaceuticals (ANIP) at Perform

Form 4 ANI PHARMACEUTICALS INC For: Aug 25 Filed by: Lalwani Nikhil

Form 4 ANI PHARMACEUTICALS INC For: Sep 15 Filed by: Lalwani Nikhil

Form 144 ANI PHARMACEUTICALS INC Filed by: Lalwani Nikhil

Form 4 ANI PHARMACEUTICALS INC For: Sep 14 Filed by: Cook Meredith

Form 4 ANI PHARMACEUTICALS INC For: Sep 11 Filed by: Thoma Jeanne

Form 144 ANI PHARMACEUTICALS INC Filed by: Thoma Jeanne

Leerink Starts ANI Pharmaceuticals (ANIP) at Outperform

ANI Pharmaceuticals to Present at September Investor Conferences

ANI Pharmaceuticals to Present at September Investor Conferences

Form 4 ANI PHARMACEUTICALS INC For: Aug 19 Filed by: Gosebruch Henry O